Prescribing Guides
Ranitidine Prescribing Guide for Indian Clinical Practice
Ranitidine prescribing guide covering the NDMA contamination withdrawal, current Indian regulatory status, H2 blocker pharmacology and NEET PG points.
MedNext Editorial Team | 2026-08-01 | 8 min read
Ranitidine Prescribing Guide for Indian Clinical Practice
Ranitidine prescribing guide covering the NDMA contamination withdrawal, current Indian regulatory status, H2 blocker pharmacology and NEET PG points.
Ranitidine was the most widely used H2 receptor antagonist in India until the global NDMA contamination crisis led to its restriction. This guide covers H2 blocker pharmacology, the regulatory status in India, alternatives, and continued NEET PG relevance.
IMPORTANT: Ranitidine has been restricted or withdrawn in many countries including India following the discovery of NDMA (N-nitrosodimethylamine) contamination. Prescribers should use alternatives such as famotidine or PPIs. The information below is provided for pharmacological education and examination preparation.
Clinical Pharmacology Overview
Ranitidine competitively blocks histamine H2 receptors on parietal cells, reducing basal and stimulated gastric acid secretion. H2 blockers inhibit acid secretion stimulated by histamine, pentagastrin, and to a lesser extent acetylcholine and gastrin. However, they cannot completely suppress acid because they only block one of the three pathways stimulating the proton pump (unlike PPIs, which block the final common pathway).
Pharmacokinetics: Oral bioavailability is approximately 50%. Protein binding is 15%. Partially metabolised hepatically; 30-70% excreted unchanged by the kidneys. Half-life is 2-3 hours. Onset of action is 1-3 hours orally and 15 minutes IV.
Indian Brand Names (Historical)
- Rantac (J.B. Chemicals) -- historically the most recognised Indian brand
- Zinetac (GSK)
- Aciloc (Cadila Healthcare)
- Histac (Ranbaxy/Sun)
- Ranitin (Torrent)
Note: Availability of these brands may be limited or discontinued due to NDMA-related regulatory actions.
Historical Indications in Indian Clinical Practice
- Peptic ulcer disease (gastric and duodenal)
- Gastro-oesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome (high doses)
- Stress ulcer prophylaxis
- Pre-anaesthetic acid aspiration prophylaxis
- Urticaria (off-label, as adjunct to H1 blockers)
Historical Dosing in Adults
Peptic ulcer: 150 mg orally twice daily or 300 mg at night for 4-8 weeks.
GERD: 150 mg orally twice daily.
Stress ulcer prophylaxis: 50 mg IV every 6-8 hours.
Pre-anaesthetic: 150 mg orally 2 hours before surgery + 150 mg the night before.
Renal impairment: reduce dose by 50% when GFR < 50 mL/min.
Important Drug Interactions
- Antacids: may reduce ranitidine absorption (separate by 1-2 hours)
- Ketoconazole, itraconazole: reduced absorption due to elevated gastric pH (class effect of acid suppressants)
- Warfarin: may slightly enhance anticoagulant effect
- Procainamide: ranitidine reduces renal clearance of procainamide
- Ranitidine does NOT inhibit CYP enzymes (unlike cimetidine) -- fewer drug interactions
Side Effects and Monitoring
Common (historical): headache, dizziness, constipation, diarrhoea.
Serious: NDMA formation (probable carcinogen) -- this is the reason for withdrawal/restriction. Other rare effects: hepatitis, interstitial nephritis, thrombocytopenia.
NDMA issue: NDMA is generated during storage (especially above 30 degrees Celsius) and through in vivo metabolism. This is an inherent property of the ranitidine molecule.
The NDMA Crisis -- Timeline
2019: An online pharmacy (Valisure) detected NDMA in ranitidine. FDA and EMA began investigations.
2020 (April): US FDA requested all manufacturers withdraw ranitidine from the market. EMA followed suit.
2020 (India): CDSCO directed suspension of manufacture and sale. Required manufacturers to test and demonstrate NDMA levels below daily acceptable intake limits (96 ng/day) before resumption.
Current status: Most Indian manufacturers have not resumed production. Famotidine and PPIs have replaced ranitidine in practice. Some formulations may still be available where manufacturers cleared NDMA testing.
Recommended Alternatives
- Famotidine: the H2 blocker of choice (no NDMA concern, more potent than ranitidine)
- Pantoprazole, rabeprazole, omeprazole: PPIs for stronger acid suppression
- Sucralfate: for mucosal protection without acid suppression
Special Populations
Pregnancy: Was Category B. Famotidine is now the preferred H2 blocker in pregnancy.
Renal impairment: Dose reduction was required.
Elderly: Was generally well tolerated. CNS effects (confusion) more common in elderly with renal impairment.
NEET PG High-Yield Points
- H2 receptor antagonist -- blocks histamine-stimulated acid secretion
- Ranitidine does NOT inhibit CYP enzymes (cimetidine does -- most tested drug interaction)
- Cimetidine: anti-androgenic effects (gynaecomastia), CYP inhibitor -- most important H2 blocker for exam drug interactions
- PPIs are superior to H2 blockers for healing peptic ulcers and GERD
- H2 blockers develop tolerance (tachyphylaxis) with continued use -- PPIs do not
- NDMA contamination and withdrawal -- increasingly tested as a drug safety topic
- H2 blockers useful for nocturnal acid breakthrough when added to PPIs
- Famotidine is now the preferred H2 blocker
Indian Regulatory Status
Ranitidine's regulatory status in India is restricted. The CDSCO suspended manufacturing and sale in 2020, and manufacturers must demonstrate NDMA levels below acceptable limits before any resumption. It was previously a Schedule H drug and was included in the NLEM. The DCGI has recommended that prescribers use alternative acid suppressants. Pharmacies are advised not to dispense existing stock unless the specific batch has been cleared for NDMA levels.
Frequently Asked Questions
Is ranitidine still available in India?
Ranitidine has been restricted in India following the NDMA contamination discovery. The CDSCO initially suspended manufacturing and sale in 2020 and subsequently required manufacturers to demonstrate NDMA levels below acceptable limits before resumption. The availability status varies -- many Indian manufacturers have not resumed production, and famotidine has largely replaced it in practice.
What was the NDMA contamination issue?
In 2019, the ranitidine molecule was found to generate N-nitrosodimethylamine (NDMA), a probable human carcinogen, during storage (especially at high temperatures) and in the body. This was an intrinsic property of the ranitidine molecule, not a manufacturing defect. The US FDA requested withdrawal of all ranitidine products from the market in April 2020.
What are the alternatives to ranitidine?
Famotidine is the most direct H2 blocker replacement (no NDMA issue). For acid suppression, PPIs (pantoprazole, rabeprazole, omeprazole) are more potent alternatives. The choice depends on the clinical indication and the need for H2 blocker-specific properties (e.g., nocturnal acid breakthrough).
Why is ranitidine still tested in NEET PG?
Ranitidine remains in the NEET PG pharmacology syllabus as the prototype H2 receptor antagonist. Questions focus on H2 blocker pharmacology, mechanism of action, comparison with PPIs, and increasingly on the NDMA safety issue. Understanding the class is essential even if ranitidine itself is restricted.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides